Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Zukunftsgestalter: Weltspitze in der Provinz: Wie der größte Pharmakonzern Deutschlands seine Führungskräfte entwickelt

Deutschlands größter Pharmakonzern lockt erfolgreich Führungskräfte nach Ingelheim – und die bleiben dank spezieller Programme lange. Probieren Sie in einem Test aus, was dafür nötig ist.

Zukunftsgestalter: Weltspitze in der Provinz: Wie der größte Pharmakonzern Deutschlands seine Führungskräfte entwickelt

We haven't written up this one. Handelsblatt has the full story — the link below goes straight to it.

Read the original at handelsblatt.com →

More in Health & Medicine

Innovent Biologics expands Phase 3 lung cancer trial globally

Biopharmaceutical manufacturer Innovent Biologics expanded its global Phase 3 MarsLight 11 clinical trial of candidate IBI363 TAK 928 to evaluate patients with immunotherapy resistant non squamous non…

  • Innovent Biologics expands MarsLight-11 Phase 3 lung cancer trial globally.
  • Trial now includes non-squamous non-small cell lung cancer patients.
  • IBI363/TAK-928 bispecific fusion protein assessed against docetaxel.

Kenya: US Delegation Backs Fight Against Period Poverty in Kenyan Schools

[Capital FM] Kisii -- A delegation of US-based leaders and humanitarian advocates is in Kenya for a week-long outreach programme aimed at tackling period poverty among schoolgirls and promoting…

  • US delegation combats period poverty in Kenyan schools
  • Provides sanitary products, menstrual hygiene education
  • Focuses on restoring dignity, ensuring school attendance

Kenya: Hospitals Risk Social Health Authority Lockout As Contracts

[Capital FM] Nairobi -- Healthcare providers across the country risk being locked out of the Social Health Authority (SHA) system from Thursday if they fail to complete the contracting process for the…

  • Kenya's hospitals may be locked out of SHA system from Oct 1, 2026, if contracts not finalized.
  • Existing contracts expire Sep 30, 2026, leaving providers without SHA access.
  • SHA urges providers to complete contracting process before Oct 1 deadline.

XtalPi files FDA application for intestinal pain drug candidate

Technology firm XtalPi submitted an Investigational New Drug application to the US Food and Drug Administration to initiate clinical trials for its gut restricted inhibitor KQTD 126

  • XtalPi submits FDA IND application for KQTD-126 intestinal pain drug.
  • KQTD-126 targets TRK family receptors to manage chronic intestinal pain.
  • Preclinical studies show pan-TRK inhibition at sub-nanomolar concentrations.

More from Monday 28 September →